Results 111 to 120 of about 125,001 (364)

Clopidogrel–Drug Interactions

Journal of the American College of Cardiology, 2011
Multidrug therapy increases the risk for drug-drug interactions. Clopidogrel, a prodrug, requires hepatic cytochrome P450 (CYP) metabolic activation to produce the active metabolite that inhibits the platelet P2Y₁₂ adenosine diphosphate (ADP) receptor, decreasing platelet activation and aggregation processes. Atorvastatin, omeprazole, and several other
Division of Cardiovascular Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan ( host institution ), Bates, Eric R., Lau, Wei C., Angiolillo, Dominick J.   +3 more
openaire   +4 more sources

Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial

British medical journal, 2019
Objective To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack ...
Yilong Wang, Weiqi Chen, Yi Lin, Xia Meng, Guohua Chen, Zhimin Wang, Jialing Wu, Dali Wang, Jianhua Li, Yibin Cao, Yuming Xu, Guohua Zhang, Xiaobo Li, Yuesong Pan, Hao Li, Xingquan Zhao, Liping Liu, Jinxi Lin, K. Dong, J. Jing, S. C. Johnston, David Wang, Yongjun Wang   +22 more
semanticscholar   +1 more source

Prevalence and prognostic value of different iron deficiency definitions in light chain cardiac amyloidosis patients

ESC Heart Failure, EarlyView.
Non‐scaled Venn diagram of iron deficiency (ID) according to various definitions and associated outcomes. The prevalence of iron deficiency was high, irrespective of the definition applied. ID defined by TSAT <20% or serum iron <13 μmol/L, rather than the guideline definition, was associated with worse outcomes.
Xinqing Li, Anran Xin, Yan Huang, Qiong Zhou, Jinxi Wang, Ping Zhou, Stefan D. Anker, Yuhui Zhang   +7 more
wiley   +1 more source

Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions

Therapeutics and Clinical Risk Management, 2015
Yolande B Saab,1 Rony Zeenny,2 Wijdan H Ramadan2 1School of Pharmacy, Pharmaceutical Sciences Department, 2School of Pharmacy, Pharmacy Practice Department, Lebanese American University, Byblos, Lebanon Purpose: Response to clopidogrel varies widely with
Saab YB, Zeenny R, Ramadan WH
doaj  

The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance

The Egyptian Heart Journal, 2014
Antiplatelet drugs play a pivotal role in the management of patients with acute coronary syndrome. Clopidogrel is an important antiplatelet drug commonly used in the treatment of those patients. However, the variability in patient response to clopidogrel
John I. Louca, George S. Mina, Bassem W. Habib, Sameh E. Sadek   +3 more
doaj   +1 more source

Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms [PDF]

, 2016
A growing body of evidence suggests that atrial fibrillation (AF) is associated with myocardial infarction (MI). However, incidence and management of MI in AF is still undefined. METHODS AND RESULTS: We searched MEDLINE via PubMed and Cochrane database
PASTORI, DANIELE, PIGNATELLI, Pasquale, Soliman, Elsayed Z, VIOLI, Francesco   +3 more
core   +1 more source

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Journal of the American Medical Association (JAMA), 2009
CONTEXT Clopidogrel therapy improves cardiovascular outcomes in patients with acute coronary syndromes and following percutaneous coronary intervention by inhibiting adenosine diphosphate (ADP)-dependent platelet activation. However, nonresponsiveness is
A. Shuldiner, J. O’Connell, K. Bliden, A. Gandhi, K. Ryan, R. Horenstein, C. Damcott, R. Pakyz, U. Tantry, Q. Gibson, T. Pollin, W. Post, A. Parsa, B. Mitchell, N. Faraday, W. Herzog, P. Gurbel   +16 more
semanticscholar   +1 more source

Dipyridamole plus aspirin versus aspirin alone in the secondary prevention after TIA or stroke: a meta-analysis by risk [PDF]

, 2008
Objectives: Our aim was to study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischemic attack or minor stroke of presumed arterial origin and to perform subgroup ...
A Algra, B Guiraud-Chaumeil, F M Yatsu, H-C Diener, L J Gray, P H A Halkes, P M W Bath   +6 more
core   +2 more sources

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago

Cardiology and Therapy
Introduction Trinidad & Tobago has the highest prevalence of cardiovascular disease (CVD) in the Caribbean and clopidogrel is a ubiquitously used treatment. Yet, the extent of genetically mediated clopidogrel resistance is unknown.
Daniele Jones, Shana Persad-Ramdeensingh, Sheherazade Crystal Abrahim, Naveen Seecheran, Rajini Rani Haraksingh   +4 more
doaj   +1 more source

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics

Cardiology Research and Practice, 2017
Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular ...
Arwa M. Amin, Lim Sheau Chin, Dzul Azri Mohamed Noor, Muhamad Ali SK Abdul Kader, Yuen Kah Hay, Baharudin Ibrahim   +5 more
doaj   +1 more source